Business
Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting
Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\nU.S. granted patent protection for ophthalmic use;U.S. granted patent protection for topical delivery, increased drug solubility and abuse deterrence;U.S. FDA provides positive response on painful dry eye development program;Panag completes a Phase 3 clinical trial for a topical pain reliever;Tetra completes four clinical trials;Serenityã trial to launch in USA and Canada; andPromised revenues to meet delivery targets. OTTAWA, June 18, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, is pleased to provide investors with an update on our research, regulatory and commercial activities. This market update covers Tetra and its subsidiaries, Panag and Tetra Natural Health (TNH).\n Tetra has grown from a small biotech to a biopharma with an enviable drug pipeline covering ophthalmic, chronic pain and oncology. The Company has completed four clinical trials providing in-depth knowledge on the safety and pharmacokinetics (how drugs are absorbed in the body) as well as preliminary data on the efficacy of several THC-CBD combinations. The Corporation acquired a large base of patent protection through its acquisition of Panag Pharma, and by forming partnerships with Altus Formulations (Altus) and Crescita Therapeutics (Crescita).  “Tetra’s pipeline is focused on large markets that represent significant potential revenues,” said Dr. Guy Chamberland, CEO and CSO of Tetra.  “Our focus on these large markets has not precluded us from actively seeking Orphan Drug Designations.  Delivering on our research promises along with solid patent protection has seen our story resonate with U.S. based institutional investors.\"  Patent Equity Developments The Corporation acquired Panag for its expertise in drug development as well as its drug pipeline and intellectual property. “This acquisition is very exciting for Tetra because it positions the Corporation as a key player in the ophthalmic inflammation and pain markets with Panag’s U.S. granted patent (U.S. patent no. 9,765,386 issued on January 24, 2017 for Compositions and Methods for Treatment of Ocular Inflammation and/or Pain),” commented Dr. Chamberland. ...